The crowd is already assembling to watch Sanofi's upcoming rollout of Afrezza, the inhaled insulin developed by MannKind.
Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.
Rising cancer drug prices aren't just alarming to payers. They're squeezing oncologists, too, at a time when doctors are paid less to administer drugs--to the point where they're selling out to hospitals.
The U.K. and Novartis have been negotiating for months now on a fair price for the Swiss pharma's meningitis B shot, Bexsero, which the country plans to add to its childhood vaccination schedule. So what's the holdup?
According to FirstWord Pharma, over the past four quarters, the 50 biggest-growing drugs delivered an absolute sales increase of $31 billion to their makers. While the top 5 slots on FWP 's list are filled with a who's who of recent, high-powered launches, AbbVie stalwart Humira is right up there with the new rollouts--and the list holds a few surprises lower down, too.
France threatened to tax hepatitis C drugmakers if they insisted on charging nosebleed prices. Apparently, the arm-twisting worked: The French government says it has cut a deal with Gilead Sciences to get Sovaldi at the lowest price in Europe.
Companies may want to invite other members of the office to the marketing party--and send specialized reps to offer a few favors.
Bolstering sales of Brilinta has been a central focus for AstraZeneca CEO Pascal Soriot as of late, and now the British drugmaker is embarking on another project designed to add some shine to the drug.
More than two dozen top-selling cancer drugs are on a hit list in the U.K. The country's Cancer Drugs Fund, designed to cover oncology meds not approved by cost-effectiveness watchdogs, plans to take a sharp look at these drugs at a meeting next month. And some of them may find themselves shut out for funding--unless new discount plans are in the offing.
Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.